Skip to content

Impact of Berberis vulgaris on Glycemic Control

Analysis of phytochemical constituents of Berberis Vulgaris Mother Tincture and evaluation of its effectiveness in comparison to Berberis Vulgaris 30C in Type 2 Diabetes Mellitus: An open-label randomized clinical trial - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099780
Enrollment
60
Registered
2025-12-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Berberis vulgaris 30C and Berberis vulgaris mother tincture.: Group 1 participants will receive Berberis vulgaris mother tincture of 10 drops diluted in half a cup of water taken orally

Sponsors

National Institute of Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with Type 2 Diabetes Mellitus as per the following laboratory parameters. Fasting Blood Sugar ranging 126 to 200 mg per dl Postprandial Blood Sugar ranging 200 to 300 mg per dl. HbA1c ranging from 6.5 to 8 percent. Patients willing to give written consent for participating in the study. Patients who can understand English, Hindi,Bengali. Patients currently on diabetic medication who are recently diagnosed ( less than 6 months) that can be safely discontinued without immediate risk and patients with no history of severe hyperglycemia, diabetic ketoacidosis, or other serious complications.

Exclusion criteria

Exclusion criteria: Presence of severe diabetic complications (retinopathy, nephropathy, cardiovascular disease). Current insulin therapy or participation in other clinical trials. Patients with severe systemic illness, immunocompromised conditions, or significant psychological disorders will be excluded. Pregnancy or lactation. Patients not willing to undergo any investigation, even after advised.

Design outcomes

Primary

MeasureTime frame
Change in HbA1cTimepoint: Baseline to 3 months and 6 months

Secondary

MeasureTime frame
Incidence of adverse events during the study. Change in FBS and PPBS levels Timepoint: Baseline to 3 months and 6 months.

Countries

India

Contacts

Public ContactDr Prabhat Tiwari

National Institute of Homoeopathy

drprabhattiwari15@gmail.com9718305515

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026